PWM
NKTR icon

Perigon Wealth Management’s Nektar Therapeutics NKTR Stock Holding History

Perigon Wealth Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-301
Closed -$77K – 841
2020
Q4 		$77K Buy
+301
New +$77.8K 0.01% 611
2020
Q3 		– Sell
-576
Closed -$200K – 393
2020
Q2 		$200K Buy
+576
New +$180K 0.03% 336
2019
Q1 		– Sell
-338
Closed -$223K – 235
2018
Q4 		$223K Buy
338
+5
+2% +$3.02K 0.06% 201
2018
Q3 		$305K Sell
333
-76
-19% -$64.9K 0.08% 171
2018
Q2 		$299K Buy
+409
New +$472K 0.09% 182
2017
Q4 		– Sell
-337
Closed -$121K – 652
2017
Q3 		$121K Buy
+337
New +$105K 0.04% 239

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Perigon Wealth Management's NKTR Position: Q1 2021 in Review

Perigon Wealth Management sold out of Nektar Therapeutics (NKTR) in Q1 2021, closing a stake of 301 shares — an estimated $77K sold.

Perigon Wealth Management first reported a position in NKTR in Q3 2017 and held it in 6 quarters. The position peaked at $305K in Q3 2018. 235 funds tracked by Wall St. Rank hold NKTR as of Q1 2021.

  • Perigon Wealth Management reported no remaining Nektar Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Perigon Wealth Management sold 301 Nektar Therapeutics shares in Q1 2021, an estimated $77K.
  • Perigon Wealth Management first reported a position in Nektar Therapeutics in Q3 2017 and held it in 6 quarters.
  • Perigon Wealth Management's Nektar Therapeutics position peaked at $305K in Q3 2018.
  • 235 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2021.

Based on Perigon Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.